

Substitute for form 1449/PTO
(Revised 07/2005)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number 10/713,860
Filing Date 11/17/03
First Named Inventor Wilson
Group Art Unit 1614
Examiner Name Hill, M.
Attorney Docket Number 049542/284259

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code - Number Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	English Language Translation Attached
	1	WO 99/64418	12-16-1999	NOVARTIS		
	2	WO 99/21555	05-06-1999	TAKEDA CHEMICAL INDUSTRIES		
	3	WO 01/74811 A2	10-11-2001	TAKEDA CHEMICAL INDUSTRIES		

OTHER DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	4	LAMBRECHT, G., "Design and Pharmacology of Selective B ₂ -Purinoceptor Antagonists," <i>Journal of Autonomic Pharmacology</i> , 1996, pp. 341-344, Vol. 16(6).	
	5	LAMBRECHT, G., "Agonists and Antagonists Acting at P2X Receptors: Selectivity Profiles and Functional Implications," <i>Naunyn-Schmiedeberg's Arch Pharmacol</i> , 2000, pp. 340-350, Vol. 362.	
Examiner Signature			Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.